Literature DB >> 8164487

Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer.

J Bourhis1, G Wilson, P Wibault, F Janot, J Bosq, J P Armand, B Luboinski, E P Malaise, F Eschwege.   

Abstract

Tumor cell kinetics were studied in vivo in a series of 97 patients with oropharyngeal cancer. The duration of S phase (tS), the labeling index (LI), and the potential doubling time (Tpot) were obtained by flow cytometry measurements of a tumor biopsy obtained after intravenous injection of 200 mg 5-bromodeoxyuridine to the patient. The mean LI was 9.7% (standard deviation [SD], 5.4), the mean tS was 10.1 hours (SD, 3.6), and the mean Tpot was 4.6 days (SD, 3.5). No significant relationship was found between the Tpot or LI and the size of the tumor, nodal status, histological grade, or the site of the primary within the oropharynx. Conversely, aneuploid tumors had longer tS (P < .001), higher LI (P < .001), and shorter Tpot (P < .05) than the diploid tumors. The mean LI and Tpot of the tumors obtained after induction chemotherapy were significantly higher and shorter, respectively, than those measured before any treatment. The data strongly suggest that rapid tumor cell proliferation frequently occurs in oropharyngeal cancer which had responded poorly to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164487     DOI: 10.1288/00005537-199404000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  9 in total

1.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

2.  Predictors of locoregional recurrence in T1-2N0 tongue cancer patients.

Authors:  Souichi Yanamoto; Shin-ichi Yamada; Hidenori Takahashi; Goro Kawasaki; Hisazumi Ikeda; Takeshi Shiraishi; Shuichi Fujita; Tohru Ikeda; Izumi Asahina; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

Review 3.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

Review 4.  Chemotherapy-induced metastasis: mechanisms and translational opportunities.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Clin Exp Metastasis       Date:  2018-01-06       Impact factor: 5.150

5.  Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer.

Authors:  Francesca Corsi; Francesco Capradossi; Andrea Pelliccia; Stefania Briganti; Emanuele Bruni; Enrico Traversa; Francesco Torino; Albrecht Reichle; Lina Ghibelli
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

6.  Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance.

Authors:  Jeanine M L Roodhart; Huanhuan He; Laura G M Daenen; Arnaud Monvoisin; Chad L Barber; Miranda van Amersfoort; Jennifer J Hofmann; Freddy Radtke; Timothy F Lane; Emile E Voest; M Luisa Iruela-Arispe
Journal:  Blood       Date:  2013-05-20       Impact factor: 22.113

Review 7.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

8.  Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy.

Authors:  Qun Zhang; Yan Wang; Jun-Fang Liao; Yu-Feng Ren; Guo-Ping Shen; Shao-Qing Niu; Wei Luo
Journal:  J Cancer       Date:  2019-06-24       Impact factor: 4.207

9.  Is hyperprogressive disease a specific phenomenom of immunotherapy?

Authors:  Marta Brambilla; Giuseppe Lo Russo; Roberto Ferrara; Sara Manglaviti; Marina Chiara Garassino; Mario Occhipinti
Journal:  Explor Target Antitumor Ther       Date:  2020-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.